Navigation Links
NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
Date:2/13/2008

DENVER, Feb. 13 /PRNewswire/ -- Rocky Mountain Biosystems, Inc.(R) (RMBI), a Denver area biomedical technology company, announced receipt of a grant award of approximately $600,000 over two years from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH) to develop its Self-Administered Vaccination Electromechanical (SAVE) technology for influenza vaccination. In the event of a pandemic, this needle-free system could be rapidly disseminated to provide protection against a deadly influenza outbreak, such as H5N1 influenza or bird flu. RMBI's technology has the potential to improve vaccine effectiveness to protect against a range of agents, including potential bioterror agents, by delivering therapeutics directly through the skin without needles, thus reducing required dosage and extending vaccine supplies. The RMBI technology and research may also improve population protection against annual seasonal influenza.

The SAVE device design is a lightweight, wristwatch-size vaccination system that delivers the vaccine in minutes, at pennies per application. "With RMBI's SAVE technology, we believe we can deliver vaccine protection to nearly all of the U.S. population within days of an outbreak. In addition, the effectiveness of RMBI's technology may reduce the amount of vaccine required, as well as provide greater immunity to the very young and elderly," noted Kevin Marchitto, RMBI's CEO.

RMBI's direct delivery through the skin is designed to 1) provide a means for individuals to immunize themselves, 2) rapidly deploy to hundreds of millions, within days of an emerging threat, 3) improve the lifetime and stability of vaccines, and their ability to be stored for long duration, and 4) improve vaccine efficiency and effectiveness to minimize chronic vaccine supply problems.

The SAVE vaccine delivery technology is being developed at Rocky Mountain Biosystems, Inc., a 6-year-old biomedical company located in the Denver metro area. RMBI blends technologies with experience to improve medical outcomes through tissue sealing and transdermal drug delivery technology to improve delivery and absorption of vaccines and therapeutics.

This release was issued through WebWire(R). For more information visit http://www.webwire.com.


'/>"/>
SOURCE Rocky Mountain Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Germany , March 29, 2017 QIAGEN ... STANDARD: QIA) today announced the U.S. launch of its ipsogen ... cleared by the U.S. Food and Drug Administration as a qualitative in vitro ... extracted from EDTA whole blood.* ... ipsogen JAK2 assay is processed on QIAGEN,s Rotor-Gene ® Q MDx ...
(Date:3/29/2017)... TIKVAH, Israel , March ... (NASDAQ: BCLI), a leading developer of adult ... financial results for the year ended December ... highly successful and pivotal year for Brainstorm, with a ... made on clinical, regulatory and operational fronts," said ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a ... the world’s food supply through enhancement of the gut microbiota, today announced the closing ... Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a number of ...
Breaking Biology Technology:
(Date:3/16/2017)... March 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... Used combined in one ... ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
Breaking Biology News(10 mins):